

## Mode of oral iron administration and the amount of iron habitually consumed do not affect iron absorption, systemic iron utilisation or zinc absorption in iron-sufficient infants: a randomised trial

Ewa A. Szymlek-Gay<sup>1\*†‡</sup>, Magnus Domellöf<sup>1</sup>, Olle Hernell<sup>1</sup>, Richard F. Hurrell<sup>2</sup>, Torbjörn Lind<sup>1</sup>, Bo Lönnnerdal<sup>3</sup>, Christophe Zeder<sup>2</sup> and Ines M. Egli<sup>2‡</sup>

<sup>1</sup>Department of Clinical Sciences, Pediatrics, Umeå University, SE-901 85 Umeå, Sweden

<sup>2</sup>Laboratory of Human Nutrition, Institute of Food, Nutrition and Health, ETH Zurich, CH-8092 Zurich, Switzerland

<sup>3</sup>Department of Nutrition, University of California, Davis, CA 95616, USA

(Submitted 9 May 2016 – Final revision received 15 July 2016 – Accepted 18 July 2016)

### Abstract

Different metabolic pathways of supplemental and fortification Fe, or inhibition of Zn absorption by Fe, may explain adverse effects of supplemental Fe in Fe-sufficient infants. We determined whether the mode of oral Fe administration or the amount habitually consumed affects Fe absorption and systemic Fe utilisation in infants, and assessed the effects of these interventions on Zn absorption, Fe and Zn status, and growth. Fe-sufficient 6-month-old infants ( $n$  72) were randomly assigned to receive 6.6 mg Fe/d from a high-Fe formula, 1.3 mg Fe/d from a low-Fe formula or 6.6 mg Fe/d from Fe drops and a formula with no added Fe for 45 d. Fractional Fe absorption, Fe utilisation and fractional Zn absorption were measured with oral (<sup>57</sup>Fe and <sup>67</sup>Zn) and intravenous (<sup>58</sup>Fe and <sup>70</sup>Zn) isotopes. Fe and Zn status, infection and growth were measured. At 45 d, Hb was 6.3 g/l higher in the high-Fe formula group compared with the Fe drops group, whereas serum ferritin was 34 and 35% higher, respectively, and serum transferrin 0.1 g/l lower in the high-Fe formula and Fe drops groups compared with the low-Fe formula group (all  $P < 0.05$ ). No intervention effects were observed on Fe absorption, Fe utilisation, Zn absorption, other Fe status indices, plasma Zn or growth. We concluded that neither supplemental or fortification Fe nor the amount of Fe habitually consumed altered Fe absorption, Fe utilisation, Zn absorption, Zn status or growth in Fe-sufficient infants. Consumption of low-Fe formula as the only source of Fe was insufficient to maintain Fe stores.

**Key words:** Infants: Iron absorption: Zinc absorption: Iron utilisation: Infant formula: Iron supplements: Randomised trials

Fe deficiency is a major public health problem worldwide<sup>(1)</sup>. Infants aged >4–6 months are at particular risk as their dietary Fe intakes are often insufficient to support increased physiological requirements during rapid growth. Fe-deficiency anaemia in early childhood has been associated with long-lasting and potentially irreversible cognitive and behavioural delays<sup>(2)</sup>. Provision of an adequate amount of Fe in infancy is therefore essential to reduce the risk of deficiency and avoid its negative effects. Both Fe supplements<sup>(3–6)</sup> and Fe-fortified formula<sup>(7–11)</sup> have been effective in improving Fe status and reducing the prevalence of Fe deficiency in young children. However, concerns have been raised about Fe supplementation of Fe-sufficient infants, including reduced infant growth<sup>(5,6,12,13)</sup> and increased morbidity<sup>(5,13)</sup>.

Fe supplements and fortification Fe appear to follow different metabolic pathways in infants, as supplemental Fe has been shown to be stored in ferritin, whereas fortification Fe seems to be utilised for Hb synthesis<sup>(14)</sup>. The different targeting has been suggested to be due to the high absorption rate of supplemental

Fe<sup>(15)</sup>, which is often provided in a single daily dose without food. This can result in a high postabsorptive peak in serum Fe, which mobilises hepcidin to divert Fe to storage<sup>(14)</sup>. High peaks in serum Fe may also lead to an increase in circulating non-transferrin-bound Fe<sup>(16)</sup>, resulting in the production of reactive oxygen species<sup>(17)</sup>. Fe-mediated oxidative stress has been proposed to be responsible for the negative effects of excessive Fe supplementation, as suggested by findings in a mouse model<sup>(18)</sup>. Recently, however, high-Fe-fortified foods consumed in infancy have also been shown to adversely affect the long-term neurodevelopment of children with initially high Hb concentrations (>128 g/l)<sup>(19)</sup> and increase morbidity in settings with high rates of infection<sup>(20)</sup>. The mechanisms behind these observations are still unknown, making it difficult to design effective yet safe programmatic strategies for the prevention of Fe deficiency in early childhood.

The adverse effects of Fe supplements or high-Fe-fortified foods on infant health and development may possibly be

\* Corresponding author: E. A. Szymlek-Gay, fax +61 3 9244 6017, email ewa.szymlekgay@deakin.edu.au

† Present address: Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.

‡ Present address: ETH Board, Zurich, Switzerland.

mediated through the negative effect of Fe on Zn absorption and subsequently Zn status<sup>(21)</sup>. Alternatively, the impairment in Zn status due to Fe intakes may occur after absorption, as excessive Fe intakes can lead to an increase in circulating non-transferrin-bound Fe<sup>(16)</sup>, which can induce the formation of reactive oxygen species and an immune response<sup>(17)</sup>, and consequently result in a decline in plasma Zn concentration<sup>(22)</sup>. Inadequate Zn status has been associated with impaired growth, poor immune function and compromised neurobehavioural function<sup>(23–25)</sup>. Zn absorption, however, appears to be reduced by Fe only when both minerals are provided together as a supplement in aqueous solutions and in disproportionate molar doses<sup>(21,26)</sup>. Whether Fe supplements given alone compromise infant Zn nutrition is still unclear<sup>(21,27–29)</sup>. When present as a fortificant, Fe does not appear to inhibit Zn absorption<sup>(30–32)</sup>, impair Zn status<sup>(32–34)</sup> or result in measurable circulating non-transferrin-bound Fe<sup>(16)</sup>. Few studies, however, have addressed this in infants. Thus, the aim of this study was to determine whether the mode of oral Fe administration (i.e. Fe supplementation *v.* fortification Fe) or the amount of Fe habitually consumed (i.e. high *v.* low Fe intakes) affects Fe absorption and systemic Fe utilisation in healthy, term, Fe-sufficient 6-month-old infants. We also determined the effects of these interventions on Zn absorption and the indicators of Fe and Zn status, as well as growth.

## Methods

### Study design and participants

This was a 45-d, partial double-blind (formula groups blinded), parallel, three-group, randomised intervention trial with a 1:1:1 participant allocation ratio. The trial was conducted from October 2010 to May 2012 in Umeå, Sweden. Infants were identified through the Swedish population register, and all those residing locally and aged 5–6 months during the recruitment period (October 2010–March 2012) were invited to participate. Infants were eligible for the trial if they were healthy, 6 months old at baseline and had been predominantly formula-fed before enrolment. Infants were excluded if they were (1) born preterm (<37 weeks of gestation), (2) had low birth weight (<2500 g), (3) had a baseline Hb concentration <100 g/l, (4) had a baseline serum ferritin concentration <12 µg/l, (5) had illness or consumed medications known to interfere with Fe or Zn absorption, (6) had ever received Fe medications or supplements, (7) were currently consuming Zn supplements or (8) had feeding problems. Previous use of Fe-fortified infant formula or Fe-fortified infant foods did not preclude participation in the trial. This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures were approved by the Ethics Committees of Umeå University (Umeå, Sweden) and ETH Zurich (Zurich, Switzerland). Written informed consent was obtained from both parents of all participating infants. This trial was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) as NCT01216709.

### Sample size

Sample size calculations were based on previous data on the incorporation of Fe-stable isotopes into erythrocytes in

infants<sup>(35)</sup>. Assuming an SD of 0.25 for log-transformed incorporation data, we estimated that twenty-one infants were required per group to detect a 40% difference in incorporation of Fe into erythrocytes between any two groups with 80% power and a two-sided  $\alpha$  of 5%. Allowing for approximately 15% attrition, twenty-four infants were enrolled in each group. The sample size calculated on the basis of this difference in incorporation of Fe into erythrocytes also allowed 80% power and a two-sided  $\alpha$  of 5% to detect a 30% difference in Zn absorption between any two groups, with the assumption of an SD of 11.0%<sup>(36)</sup>.

### Randomisation and blinding

A computer-generated, permuted-block (block size,  $n = 3$ ) randomisation sequence with stratification by sex was used to randomly assign seventy-two eligible infants to one of three groups: high-Fe formula ( $n = 24$ ), low-Fe formula ( $n = 24$ ) or Fe drops ( $n = 24$ ); three-digit codes were used to indicate the treatment groups. Infants were enrolled and assigned to the interventions by two paediatric research nurses who were blinded to the allocation sequence. Allocation concealment was achieved via secure storage of the randomisation sequence separately from the participant database. Neither the trial participants nor the researchers were aware of the formula group assignment. The codes were broken when data collection, biochemical analyses and data entry were completed.

### Interventions and adherence

For the duration of this 45-d study, parents were asked to feed their infant daily (except for day 31: Fe and Zn absorption test day) 534 ml of high-Fe formula (high-Fe formula group), low-Fe formula (low-Fe formula group) or formula with no added Fe (Fe drops group). The formulae were identical in appearance, taste and composition with the exception of Fe content. The formulae were manufactured by Semper AB, Sweden, and had the following analysed nutrient content: 12.4 mg Fe as ferrous sulphate/l (95.0 mg Fe/kg powdered formula), 3.9 mg Zn/l, 132.0 mg ascorbic acid/l and 13.4 g protein/l in the high-Fe formula; 2.3 mg Fe as ferrous sulphate/l (18.0 mg Fe/kg powdered formula), 3.9 mg Zn/l, 131.3 mg ascorbic acid/l and 13.2 g protein/l in the low-Fe formula; and 0.5 mg Fe/l (4.0 mg Fe/kg powdered formula), 3.8 mg Zn/l, 131.3 mg ascorbic acid/l and 13.1 g protein/l in the formula with no added Fe. The formulae were packaged into identical foil bags. The bags were marked with only the three-digit randomisation code. The formulae were provided to the parents as powder in pre-weighed daily portions of 69.5 g. Parents were asked to mix this quantity of formula with 480 ml of water. To ensure correct formula dilutions, parents were given a 500-ml graduated cylinder to assist with the measuring of water. Each parent was asked to feed their infant the assigned formula as three meals each day. Parents of infants in the Fe drops group were also asked to give their child 0.42 ml of oral Fe drops daily in a single dose (except for day 31: Fe and Zn absorption test day) between meals for the duration of the study (15.0 mg Fe as ferrous sulphate/ml; Ferrous Sulfate Iron Supplement Drops; Hi-Tech Pharmaceutical Co. Inc.). To allow for accurate administration of Fe

drops, parents were given a 1-ml graduated oral syringe. The assigned quantity of study formulae (i.e. 534 ml/d of either high-Fe or low-Fe formula, depending on the infants' group assignment) provided infants in the high-Fe formula group with 6.6 mg Fe/d and infants in the low-Fe formula group with 1.3 mg Fe/d. The formula with no added Fe (i.e. 534 ml/d) and Fe drops (i.e. 0.42 ml/d) provided infants in the Fe drops group with 6.6 mg Fe/d. During the study, infants were not permitted to consume Fe- or Zn-fortified commercial infant foods, non-study infant formula, Fe- or Zn-fortified foods, animal tissue-containing foods, or Fe- or Zn-containing supplements. Infants were allowed to consume *ad libitum* the following foods provided by the study: infant formula with no added Fe (0.5 mg Fe/l; Semper AB), rice porridge with no added Fe (Oldana AB) and a range of commercially made fruit- and vegetable-based infant foods with no added Fe or Zn and free from animal tissue (Semper AB). Parents were also permitted to feed their infants home-made fruit and vegetable purées. Mothers were able to continue to breast-feed at their discretion.

Adherence to the intervention was assessed by asking each parent to record daily the amount of formula consumed by their infant. Parents of infants in the Fe drops group were also asked to record the volume of drops given to their infant each day and note any case of vomiting or possetting by their infant up to 30 min after the administration of the drops. The adherence data were used to estimate mean daily intakes of study formulae, Fe drops, and Fe and Zn intakes from the interventions.

#### *Socio-demographic, anthropometric, obstetric and neonatal data*

Socio-demographic data were collected at baseline using a self-administered questionnaire. Nude weight was measured to the nearest 5 g with digital baby scales (Seca 727; Seca Deutschland). Recumbent length was measured to the nearest 0.1 cm with a paediatric length board (CMS Weighing Equipment Ltd). A non-stretchable measuring tape for head circumference of babies and toddlers (Seca 212; Seca Deutschland) was used to assess each child's head circumference to the nearest 0.1 cm. Knee-heel length was measured to the nearest 0.1 cm with an infant knemometer (BK5; FORCE Instituttet). All measurements were taken in accordance with standardised procedures<sup>(37)</sup>. Weight, length and head circumference were measured in duplicate, whereas knee-heel length was measured four times at baseline and at the end of the study. Additional duplicate measurements were taken for weight on day 31. The *z* scores for weight-for-age, length-for-age and head circumference-for-age were calculated using the World Health Organization Child Growth Standards<sup>(38)</sup>. Obstetric and neonatal data were obtained from hospital records.

#### *Preparation and administration of isotopes*

Fe absorption, systemic Fe utilisation and Zn absorption were measured using stable-isotope methods. <sup>57</sup>Fe (97.8% enrichment), <sup>58</sup>Fe (99.5% enrichment), <sup>67</sup>ZnO (90.6% enrichment) and <sup>70</sup>ZnO (95.4% enrichment) were purchased from Chemgas. All isotopic labels were prepared at the Human Nutrition Laboratory at ETH Zurich. <sup>57</sup>FeSO<sub>4</sub> for oral administration was prepared by dissolving <sup>57</sup>Fe in diluted H<sub>2</sub>SO<sub>4</sub>. The solution was

divided into vials containing 0.67 mg <sup>57</sup>Fe (administered to the formula groups) or 2 mg <sup>57</sup>Fe (administered to the Fe drops group) in 0.5 ml of solution. <sup>67</sup>ZnSO<sub>4</sub> for oral administration was prepared by dissolution of <sup>67</sup>ZnO in stoichiometric amounts of diluted H<sub>2</sub>SO<sub>4</sub>. The resulting <sup>67</sup>ZnSO<sub>4</sub> solution was subsequently diluted to a Zn concentration of 0.33 mg/g and then aliquoted into vials containing 0.17 mg <sup>67</sup>Zn in 0.5 ml of solution. [<sup>58</sup>Fe]citrate was prepared for intravenous infusion from <sup>58</sup>Fe as previously described<sup>(39)</sup>. The solution was aliquoted into vials containing 50 µg <sup>58</sup>Fe in 1 ml of solution. <sup>70</sup>ZnCl<sub>2</sub> was prepared for intravenous infusion by converting <sup>70</sup>ZnO to <sup>70</sup>ZnCl<sub>2</sub> with diluted HCl adjusted to pH 6 by adding NaHCO<sub>3</sub> and diluted by physiological saline to a final Zn concentration of 100 µg/g. The solution was then divided into vials containing 100 µg <sup>70</sup>Zn in 1 ml of solution. All vials containing <sup>58</sup>Fe and <sup>70</sup>Zn were sterilised and checked for sterility and pyrogens at the Cantonal Pharmacy of the University Hospital Zurich.

The isotopes were administered to each infant at 7.3 months of age (ranging from 6.9–7.8 months) on study day 31. The high-Fe formula, formula with no added Fe and Fe drops used on the day of testing were the same as the ones used for the intervention as described above. The formula (either high-Fe formula or formula with no added Fe, depending on the infant's group assignment) was prepared freshly on the day of testing.

Infants in both formula groups received three meals of 150 ml of high-Fe formula; 0.67 mg <sup>57</sup>Fe and 0.17 mg <sup>67</sup>Zn were added to each meal (2 mg <sup>57</sup>Fe and 0.5 mg <sup>67</sup>Zn in total for all three meals) before feeding. The first meal was administered after a 2-h fast, with the second and third meal fed to infants 2 h after the previous meal had been ingested. Each meal was fed under standardised conditions over 15–20 min. After each meal, 6 ml × 2 of unlabelled high-Fe formula was administered to each infant to rinse out the bottle. The bottle was weighed immediately before and after feeding. All spills, possetting and other accidental milk losses were removed with pre-weighed napkins. The amount of <sup>57</sup>Fe and <sup>67</sup>Zn consumed by each infant was calculated by subtracting the amount of <sup>57</sup>Fe and <sup>67</sup>Zn corresponding to the amount of meal left in the bottle and absorbed in the napkins from the original doses of 0.67 mg <sup>57</sup>Fe and 0.17 mg <sup>67</sup>Zn. Next, 30 min after the first meal had been ingested, 1 ml of an aqueous solution containing 50 µg <sup>58</sup>Fe and 1 ml of an aqueous solution containing 100 µg <sup>70</sup>Zn were aspirated into a syringe, injected into a 25-ml infusion bag (0.9% saline) and infused over 30 min into each infant in the formula groups. The rate of intravenous infusion of Fe was based on the estimated 2 µg/min plasma appearance of Fe normally absorbed from the gastrointestinal tract<sup>(40)</sup>. At completion of the infusion, 5 ml of unlabelled saline was injected into the bag to rinse it out and the saline was infused into the infant. This was carried out twice, and we assumed that no residual isotopes remained in the infusion bag.

Infants in the Fe drops group followed a similar protocol as the formula groups. The Fe drops group received three meals of 150 ml of formula with no added Fe; 0.17 mg <sup>67</sup>Zn was added to each meal (0.5 mg <sup>67</sup>Zn in total for all three meals) before feeding. The first meal was administered after a 2-h fast. Next, 2 h after the first test meal had been ingested, infants in the Fe drops group were administered 0.4 ml of Fe drops labelled with 2 mg

$^{57}\text{Fe}$ ; 30 min after the administration of Fe drops, 1 ml of an aqueous solution containing  $50\ \mu\text{g}$   $^{58}\text{Fe}$  and 1 ml of an aqueous solution containing  $100\ \mu\text{g}$   $^{70}\text{Zn}$  were aspirated into a syringe, injected into a 25-ml infusion bag (0.9% saline) and infused over 30 min into each infant in the Fe drops group. At completion of the infusion,  $5\ \text{ml} \times 2$  of unlabelled saline was injected into the infusion bag to rinse it out, and the saline was infused into the infant; we assumed that no residual isotopes remained in the infusion bag. Immediately following administration of the intravenous dose, infants were fed the second meal with the third one fed to infants 2 h after the second meal had been ingested. Each meal was fed under standardised conditions over 15–20 min. After each meal,  $6\ \text{ml} \times 2$  of unlabelled formula with no added Fe was administered to each infant to rinse out the bottle. The bottle was weighed immediately before and after feeding. All spills, possetting and other accidental milk losses were removed with pre-weighed napkins. The amount of  $^{67}\text{Zn}$  consumed by each infant was calculated by subtracting the amount of  $^{67}\text{Zn}$  corresponding to the amount of meal left in the bottle and absorbed in the napkins from the original dose of 0.17 mg.

Neither the formula groups nor the Fe drops group was permitted to consume any food or drink on the day of testing until 2 h after the third meal had been ingested. On the day of testing, the formula groups received a total of 8.1 mg Fe and 2.5 mg Zn, and the Fe drops group received a total of 8.3 mg Fe and 2.4 mg Zn (i.e. Fe/Zn in the test meals/Fe drops plus the isotope labels). This amount of Fe is equivalent to 1 mg Fe/kg body weight, assuming a mean body weight of 8 kg at 7 months<sup>(41)</sup>.

#### Sample collection

Venous blood samples were drawn at baseline, on day 31 and at the end of the study (day 45) after a 2-h fast for the determination of Fe and Zn status indices (each time point), as well as Fe isotopic composition (day 45 samples only). The day 31 samples were collected before the administration of stable isotopes. Samples were collected by experienced paediatric research nurses into an EDTA-containing tube, a serum separator tube and a heparinised trace element-free tube (Becton, Dickinson and Company). The time of sample collection was recorded. Baseline sampling and end-of-study sampling were postponed by 2 weeks if the child was ill or recently immunised to minimise the influence of an acute-phase response on blood indices. A spot urine sample was collected 96 h after the infusion with stable isotopes and stored at  $-20^\circ\text{C}$  until Zn isotopic composition determination<sup>(42)</sup>.

#### Laboratory analyses

Hb, mean corpuscular volume, serum ferritin, serum Fe and serum transferrin were analysed within 2–4 h of collection at the Department of Clinical Chemistry, Umeå University, Sweden. Hb and mean corpuscular volume were measured in whole blood using a Sysmex XE-5000 Automated Haematology Analyser (Sysmex). Blood in the serum separator tube was centrifuged for 10 min at 3000 rpm, and the separated serum was analysed for ferritin using a Roche Cobas 6000 (Roche Diagnostics), and Fe and transferrin were analysed using a

Vitros 5.1 FS (Ortho Clinical, Johnson & Johnson AB). Values for the controls were within the certified ranges for all analyses. Serum Fe and transferrin concentrations were used to calculate transferrin saturation using the following formula: transferrin saturation (%) = serum Fe ( $\mu\text{mol/l}$ ) / (serum transferrin (g/l)  $\times$  25.1)  $\times$  100<sup>(43)</sup>. The remaining serum was stored at  $-80^\circ\text{C}$  until hepcidin and high-sensitivity C-reactive protein analyses. Hepcidin and high-sensitivity C-reactive protein were determined at the Department of Clinical Sciences, Pediatrics, Umeå University, Sweden, by an enzyme immunoassay using commercial kits (Human Hepcidin Kit S-1337; Bachem AG, and Human C-Reactive Protein, Quantikine<sup>®</sup> ELISA; R&D Systems Europe Ltd, respectively). Analytical accuracy was checked by analysing in-house serum controls at low and high concentrations. For hepcidin, the analysed mean values for the quality control sera were 25.9 (SD 2.4; CV 9.3%;  $n$  5)  $\mu\text{g/l}$  at 25.0  $\mu\text{g/l}$  (low concentration) and 42.8 (SD 5.2; CV 12.3%;  $n$  5)  $\mu\text{g/l}$  at 40.0  $\mu\text{g/l}$  (high concentration). For high-sensitivity C-reactive protein, the analysed mean values for the quality control sera were 154.5 (SD 14.5; CV 9.4%;  $n$  6) ng/ml at 150 ng/ml (low concentration) and 3137.7 (SD 202.4; CV 6.4%;  $n$  6) ng/ml at 3000 ng/ml (high concentration).

Blood samples in the heparinised trace element-free tube were refrigerated immediately after collection. Plasma was separated within 2 h and stored at  $-80^\circ\text{C}$  until Zn analysis. For day 45 samples, erythrocytes were stored at  $-20^\circ\text{C}$  for determining Fe isotopic composition. Zn concentration and Fe isotopic composition were measured at the Human Nutrition Laboratory at ETH Zurich. Zn was measured using flame atomic absorption spectrophotometry (Varian AA240FS; Varian Inc.) after dilution with 10%  $\text{HNO}_3$  using commercial aqueous standards (Titrisol; Merck) for external calibration. Analytical accuracy was checked by analysis of commercially available serum controls (Seronorm Trace Elements Serum Levels 1 and 2; Sero AS). The analysed mean values for the quality control sera were 25.4 (SD 0.6;  $n$  5)  $\mu\text{mol/l}$  for Level 1 and 31.3 (SD 0.6;  $n$  5)  $\mu\text{mol/l}$  for Level 2. The certified values were 24.1–29.2  $\mu\text{mol/l}$  for Level 1 and 27.1–47.5  $\mu\text{mol/l}$  for Level 2. The method showed a detection limit of 0.50  $\mu\text{mol/l}$  and its intra-assay and inter-assay CV were 3 and 5%, respectively. For Fe isotopic analysis, erythrocytes were first mineralised by microwave digestion, and Fe was then separated by anion-exchange chromatography followed by a solvent–solvent extraction step into diethyl ether<sup>(44)</sup>. Fe isotopic composition was measured by negative thermal ionisation–MS using a magnetic sector field MS (Finnigan MAT 262; Thermo Finnigan), equipped with a multi-collector system for simultaneous ion beam detection<sup>(44)</sup>. Circulating Fe was determined for each infant using an assumed blood volume of 65 ml/kg<sup>(45)</sup>, the measured Hb concentration and the known concentration of Fe in Hb of 3.47 mg/g. Fractional incorporation of  $^{57}\text{Fe}$  and  $^{58}\text{Fe}$  into erythrocytes 14 d after isotope administration was calculated according to isotopic dilution principles as described earlier<sup>(44)</sup>. The erythrocyte incorporation of  $^{58}\text{Fe}$  indicates Fe utilisation. The absorption of  $^{57}\text{Fe}$  was calculated by dividing the percentage of erythrocyte incorporation of  $^{57}\text{Fe}$  by the fractional erythrocyte incorporation of  $^{58}\text{Fe}$ .

Urine samples were analysed for Zn isotopic composition under chemical blank monitoring at the Human Nutrition



Laboratory at ETH Zurich. Samples were concentrated by freeze-drying, mineralised by microwave digestion (MLS-ETHOS plus; MLS GmbH) using a mixture of HNO<sub>3</sub> and H<sub>2</sub>O<sub>2</sub>, and Zn was then separated from the sample matrix by anion-exchange chromatography as described previously<sup>(46)</sup>. All acids used for the preparation of samples were ultrapure. <sup>70</sup>Zn-to-<sup>66</sup>Zn:<sup>67</sup>Zn-to-<sup>66</sup>Zn ratios were measured to determine <sup>70</sup>Zn and <sup>67</sup>Zn enrichment in the urine samples by inductively coupled plasma MS using a high-resolution, double-focusing, magnetic sector field multi-collector MS (Neptune; Thermo-Finnigan). Fractional absorption of <sup>67</sup>Zn was calculated from <sup>67</sup>Zn:<sup>70</sup>Zn ratios as described by Friel *et al.*<sup>(47)</sup>.

Fe deficiency was defined as depleted Fe stores, Fe-deficient erythropoiesis and Fe-deficiency anaemia<sup>(48)</sup>. Depleted Fe stores were defined as a serum ferritin concentration <12 µg/l<sup>(49)</sup> in the absence of Fe-deficient erythropoiesis or Fe-deficiency anaemia. Fe-deficient erythropoiesis was defined as ≥2 abnormal values for serum ferritin (<12 µg/l), mean corpuscular volume (<71 fl)<sup>(50)</sup> and transferrin saturation (<10%)<sup>(51)</sup> in the absence of anaemia (Hb ≥100 g/l). Fe-deficiency anaemia was defined as Hb <100 g/l<sup>(50)</sup> in the presence of Fe-deficient erythropoiesis. Infants with missing data at each time point for serum ferritin, mean corpuscular volume, transferrin saturation or Hb were excluded from these estimations. Low plasma Zn concentration was defined as <9.9 µmol/l for morning samples and <8.7 µmol/l for samples drawn afternoon<sup>(52)</sup>. Fe and Zn deficiency prevalence was estimated after correcting serum ferritin and plasma Zn concentrations for infection for all infants with a C-reactive protein concentration >5 mg/l at baseline, day 31 or day 45 (*n* 7 at baseline, *n* 4 on day 31 and *n* 5 on day 45) as described previously<sup>(53,54)</sup>.

### Statistical analysis

The primary outcomes were Fe absorption and systemic Fe utilisation. The secondary outcomes were Zn absorption and the indices of Fe and Zn status and growth. Descriptive statistics were used to examine participants' characteristics at birth and baseline. To compare outcomes measured at more than one time point among the three intervention groups (i.e. Fe status indices, plasma Zn concentration and growth indices), in order to utilise all data, we used linear random-intercept models with robust standard errors where repeated measurements were nested within individuals. All models included fixed effects of time and group and their interaction in order to assess differences in change within and between groups. Adjustments were made for *a priori*-defined covariates: sex and infection (Fe status indices), time of day of blood sampling and infection (plasma Zn), and sex (growth indices). To compare outcomes measured at only one time point among the three groups (i.e. Fe absorption, Fe utilisation and Zn absorption), we used linear regression analyses with robust standard errors. Linear regression models were used to examine the relationship between Fe absorption and Fe utilisation and Fe status indices at day 31; Hb, mean corpuscular volume, serum Fe, serum transferrin, transferrin saturation and serum hepcidin measures were excluded for all infants with a C-reactive protein concentration >5 mg/l, whereas serum ferritin was corrected for infection for all infants

with a C-reactive protein concentration >5 mg/l<sup>(53)</sup>. The distributions of residuals from all models were examined, and log-transformations were used where residuals were skewed or exhibited non-constant variance. Where log-transformations were used, results are shown as ratios of geometric means rather than differences of arithmetic means.

Prevalence of Fe deficiency and low plasma Zn concentration was assessed at three time points, and thus random-intercept logistic regression analyses where repeated measurements were nested within individuals were used to assess group effects.

As infants had up to 45 d of adherence data, generalised estimating equation models with exchangeable correlation structures were used to assess differences among the study groups in study formula intakes and Fe and Zn intakes from the interventions.

All analyses were performed with Stata (version 13.1; Stata-Corp LP). All tests were two-sided and were not adjusted for multiple testing. Statistical significance was determined at *P* < 0.05.

## Results

### Participants

Invitation letters, followed up by telephone calls, were sent to parents of 2429 infants. Of these, 160 expressed initial interest in participation and ninety-seven were assessed for eligibility. The screening process identified seventy-two eligible infants who were randomly assigned to one of the three intervention groups (Fig. 1). All infants received their allocated intervention; six infants (8.3%) were lost to follow-up.

The mean age of infants at baseline was 6.1 (SD 0.3) months, and the mean gestational age was 40.1 (SD 1.3) weeks. The majority of infants were boys, were born via vaginal delivery, were not breast-fed at baseline and were from middle-income families. In all, 50% of mothers had university education. All infants and their mothers were born in Sweden, and all infants' anthropometric birth indices were within the normal range (Table 1).

### Adherence to intervention

The mean amount of study formula consumed during the trial was 516 (95% CI 511, 522) ml/d in the high-Fe formula group, 508 (95% CI 500, 516) ml/d in the low-Fe formula group and 503 (95% CI 488, 518) ml/d in the Fe drops group. There was no statistically significant difference among the three groups in the daily amount of study formula consumed during the intervention period (*P* = 0.092).

The required volume of Fe drops (i.e. 0.42 ml/d) was administered to infants in the Fe drops group on 99.9% of occasions. Accounting for vomiting and possetting, 0.42 ml of Fe drops/d were consumed by infants in the Fe drops group on 95.2% of occasions. This resulted in the Fe drops group consuming a mean of 0.39 (95% CI 0.37, 0.42) ml/d of Fe drops.

During the intervention, the study formulae provided 6.4 (95% CI 6.3, 6.4) mg Fe/d to infants in the high-Fe formula group, and 1.2 (95% CI 1.2, 1.2) mg Fe/d to infants in the low-Fe formula group. The formula with no added Fe combined




Fig. 1. Flow chart of participants through the study.

**Table 1.** Characteristics of infants at birth and baseline (Numbers and percentages; mean values and standard deviations)

	High-Fe formula (n 24)		Low-Fe formula (n 24)		Fe drops (n 24)	
	n	%	n	%	n	%
Age (months)						
Mean		6.1		6.1		6.1
SD		0.2		0.3		0.3
Female	11	45.8	11	45.8	11	45.8
Vaginal delivery	20	83.3	20	83.3	22	91.7
Gestational age (weeks)						
Mean		39.4		40.3		40.6
SD		1.3		1.3		1.0
Birth weight (kg)						
Mean		3.6		3.7		3.8
SD		0.6		0.5		0.4
Birth length (cm)						
Mean		50.3		50.8		51.5
SD		1.8		2.1		1.9
Birth head circumference (cm)						
Mean		35.0		35.3		35.8
SD		1.4		1.6		1.3
Breast-fed at baseline	4	16.7	2	8.3	4	16.7
Mother and infant born in Sweden	24	100.0	24	100.0	24	100.0
Mother with university education	12	50.0	14	58.3	10	41.7
Income*						
<SEK240 000	2	8.3	8	33.3	6	25.0
SEK240 000–SEK479 999	18	75.0	13	54.2	14	58.3
≥SEK480 000	1	4.2	2	8.3	2	8.3

\* Annual post-tax household income. SEK240 000 approximately USD29 000. SEK480 000 approximately USD58 000. Columns do not sum to 100 % because some parents chose not to answer the question.

with Fe drops provided 5.7 (95 % CI 5.1, 6.3) mg Fe/d to infants in the Fe drops group. Fe intakes from the interventions differed among groups ( $P < 0.001$ ) and were higher in the high-Fe

formula group compared with the low-Fe formula group (mean difference: 5.2 (95 % CI 4.8, 5.5) mg Fe/d,  $P < 0.001$ ), higher in the high-Fe formula group compared with the Fe drops group

(mean difference: 0.6 (95% CI 0.3, 1.0) mg Fe/d,  $P=0.001$ ) and higher in the Fe drops group compared with the low-Fe formula group (mean difference: 4.6 (95% CI 4.2, 4.9) mg Fe/d,  $P<0.001$ ).

The high-Fe formula group received 2.0 (95% CI 2.0, 2.0) mg Zn/d, the low-Fe formula group received 2.0 (95% CI 1.9, 2.0) mg Zn/d and the Fe drops group received 1.9 (95% CI 1.9, 2.0) mg Zn/d from the study formulae. Compared with the Fe drops group, Zn intakes from the study formulae were higher in both the high-Fe formula group (mean difference: 0.1 (95% CI 0.1, 0.2) mg Zn/d,  $P<0.001$ ) and the low-Fe formula group (mean difference: 0.1 (95% CI 0.0, 0.1) mg Zn/d,  $P=0.007$ ).

### Iron and zinc status

By 45 d, mean Hb concentration decreased from baseline by 4.9 (95% CI -8.3, -1.4) g/l in the Fe drops group with no evidence of a change in the high-Fe formula or low-Fe formula groups (Table 2). Because of the decrease in Hb concentration in the Fe drops group, at the end of the study, there was a significant difference in change in the mean Hb concentration between the high-Fe formula and Fe drops groups (intervention effect: 6.3 (95% CI 1.4, 11.2) g/l). At the end of the study, Hb concentration also tended to be 3.8 (95% CI -0.6, 8.2) g/l higher in the high-Fe formula group than in the low-Fe formula group ( $P=0.088$ ). Within-group comparisons showed a 32 (95% CI 22, 40)% decrease in mean serum ferritin concentration from baseline in the low-Fe formula group with no evidence for a change in the high-Fe formula or Fe drops groups (Table 2). Compared with the low-Fe formula group, at the end of the study, mean serum ferritin concentration was 34 (95% CI 4, 72)% greater in the high-Fe formula group, and 35 (95% CI 7, 72)% greater in the Fe drops group. There was no evidence of a change in mean serum transferrin concentration from baseline in the high-Fe formula or Fe drops groups, whereas it significantly increased in the low-Fe formula group, with a mean intervention effect of -0.1 (95% CI -0.2, 0.0) g/l when both the high-Fe formula group's and Fe drops group's values were compared with those of the low-Fe formula group (Table 2). Serum hepcidin concentrations decreased from baseline in all three study groups (all  $P\leq 0.022$ ) with no evidence that these changes were related to the intervention ( $P=0.908$ ). Similarly, despite the significant decrease in mean plasma Zn concentration from baseline in the high-Fe formula group ( $P=0.020$ ), there was no evidence of significant intervention-related changes in plasma Zn concentrations for the three study groups ( $P=0.342$ ). There was no evidence of intervention effects on mean corpuscular volume, serum Fe concentration or transferrin saturation (Table 2).

At baseline, one infant had Fe-deficient erythropoiesis (Fe drops group). At the end of the study, all infants were Fe sufficient (data not shown in tables). In all, five infants had low plasma Zn concentrations at baseline (three in the high-Fe formula group and two in the low-Fe formula group) and three at the end of the study (two in the high-Fe formula group and one in the low-Fe formula group) (data not shown in tables). The intervention had no effect on the risk of developing Fe or Zn deficiency (all  $P\geq 0.760$ ).

### Growth

Within-group comparisons showed that mean weight, length, head circumference and knee-heel length increased from baseline in all three study groups (Table 3; all  $P<0.001$ ). We found no evidence of intervention effects on weight, length, head circumference or knee-heel length (Table 3; all  $P\geq 0.052$ ).

Weight-for-age, length-for-age and head circumference-for-age  $z$  scores were within the normal range for all infants at all time points (data not shown in tables). Only weight-for-age  $z$  scores significantly increased from baseline within each group (high-Fe formula group: 0.17 (95% CI 0.06, 0.28),  $P=0.002$ ; low-Fe formula group: 0.13 (95% CI 0.03, 0.23),  $P=0.013$ ; and Fe drops group: 0.11 (95% CI 0.00, 0.21),  $P=0.046$ ). Head circumference-for-age  $z$  scores increased from baseline in the low-Fe formula group (0.14 (95% CI 0.05, 0.22),  $P=0.002$ ) and the Fe drops group (0.11 (95% CI 0.02, 0.21),  $P=0.018$ ) but not in the high-Fe formula group (0.01 (95% CI -0.10, 0.11),  $P=0.900$ ). We observed no within-group changes for length-for-age  $z$  scores in any of the three groups (all  $P\geq 0.232$ ) (data not shown in tables). There was no evidence of intervention effects on weight-for-age ( $P=0.708$ ), length-for-age ( $P=0.734$ ) or head circumference-for-age ( $P=0.142$ )  $z$  scores (data not shown in tables).

### Iron absorption and utilisation

There was no evidence that mean fractional Fe absorption or erythrocyte Fe utilisation differed among the three study groups (Table 4; all  $P\geq 0.534$ ). Fe absorption was inversely correlated with serum ferritin concentration (Table 5, Fig. 2), such that a 10% increase in serum ferritin (e.g. an increase from 60 to 66  $\mu\text{g/l}$ ) corresponded to a 3.9% decrease in Fe absorption in the high-Fe formula group, a 5.6% decrease in the low-Fe formula group and a 4.8% decrease in the Fe drops group. Fe absorption was also inversely correlated with serum hepcidin concentration (Table 5, Fig. 3), with each 10% increase in serum hepcidin (e.g. an increase from 40 to 44  $\mu\text{g/l}$ ) relating to a 2.6% decrease in Fe absorption in the high-Fe formula group, a 6.5% decrease in the low-Fe formula group and a 5.0% decrease in the Fe drops group. In the low-Fe formula group only, Fe absorption was positively associated with serum Fe concentration, serum transferrin concentration and transferrin saturation (Table 5). The associations between Fe absorption and Hb concentration and mean corpuscular volume were not significant in any of the intervention groups (Table 5; all  $P\geq 0.216$ ). Fe utilisation was negatively correlated with mean corpuscular volume only in the low-Fe formula group ( $r=-0.541$ ,  $P=0.011$ ,  $n=21$ ). Fe utilisation did not significantly correlate with Hb, serum ferritin, serum Fe, serum transferrin, transferrin saturation or serum hepcidin in any of the three groups (all  $P\geq 0.071$ ; data not shown in the tables).

### Zinc absorption

There was no evidence that mean fractional Zn absorption differed among the three study groups (Table 4;  $P=0.284$ ).

**Table 2.** Adjusted means at baseline, day 31 and day 45 with estimates of intervention effect for Hb, mean corpuscular volume, serum ferritin, serum iron, serum transferrin, transferrin saturation, serum hepcidin and plasma zinc in the three study groups\* (Arithmetic/geometric means and 95 % confidence intervals)

	Study group						Intervention effect†						<i>P</i> <sub>for intervention effect</sub>
	High-Fe formula		Low-Fe formula		Fe drops		High-Fe formula v. low-Fe formula		High-Fe formula v. Fe drops		Fe drops v. low-Fe formula		
	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	
<b>Hb (g/l)‡§</b>	24, 23, 21		24, 23, 22		24, 20, 20								
<i>n</i>	24, 23, 21		24, 23, 22		24, 20, 20								
Baseline	110.9	108.2, 113.5	112.5	109.5, 115.4	117.5	112.6, 122.4							
Day 31	113.2	110.2, 116.2	115.0	111.9, 118.2	115.1	112.0, 118.2							
Day 45	112.3	109.6, 115.0	110.1	107.5, 112.7	112.7	109.7, 115.7							
Change from baseline to day 45¶	1.4	-1.9, 4.7	-2.4	-5.3, 0.5	-4.9	-8.3, -1.4	3.8	-0.6, 8.2	6.3	1.4, 11.2	-2.5	-6.9, 2.0	0.037
<i>P</i> for within- or between-group comparison**	0.390		0.105		0.006		0.088		0.011		0.279		
<b>Mean corpuscular volume (fl)‡§</b>	24, 23, 21		24, 23, 22		24, 20, 20								
<i>n</i>	24, 23, 21		24, 23, 22		24, 20, 20								
Baseline	76.1	74.4, 77.8	77.6	76.6, 78.5	76.7	75.7, 77.8							
Day 31	76.1	74.5, 77.7	77.6	76.5, 78.8	77.1	75.9, 78.2							
Day 45	75.8	74.2, 77.3	77.2	76.2, 78.1	77.0	75.7, 78.3							
Change from baseline to day 45¶	-0.4	-1.0, 0.3	-0.4	-1.1, 0.3	0.3	-0.3, 0.9	0.0	-0.9, 0.9	-0.7	-1.6, 0.2	0.7	-0.2, 1.6	0.198
<i>P</i> for within- or between-group comparison**	0.254		0.227		0.316		0.953		0.128		0.119		
<b>Serum ferritin (µg/l)§††</b>	24, 23, 22		24, 23, 22		24, 20, 19								
<i>n</i>	24, 23, 22		24, 23, 22		24, 20, 19								
Baseline	61.0	51.2, 72.6	72.8	58.2, 91.0	84.1	66.0, 107.2							
Day 31	57.7	47.6, 70.1	57.0	43.8, 74.1	72.6	58.8, 89.7							
Day 45	55.7	44.7, 69.4	49.7	38.6, 63.9	77.8	63.0, 96.2							
Change from baseline to day 45‡‡	0.91	0.74, 1.13	0.68	0.60, 0.78	0.92	0.76, 1.13	1.34	1.04, 1.72	0.99	0.73, 1.32	1.35	1.07, 1.72	0.011
<i>P</i> for within- or between-group comparison**	0.401		<0.001		0.453		0.021		0.927		0.012		
<b>Serum Fe (µmol/l)‡§</b>	24, 23, 22		23, 23, 20		22, 20, 18								
<i>n</i>	24, 23, 22		23, 23, 20		22, 20, 18								
Baseline	9.0	7.8, 10.3	9.3	7.8, 10.7	9.0	7.6, 10.5							
Day 31	8.7	7.5, 10.0	10.0	8.4, 11.5	10.1	8.4, 11.8							
Day 45	8.4	7.1, 9.6	8.6	6.9, 10.4	9.7	8.0, 11.3							
Change from baseline to day 45¶	-0.7	-2.6, 1.2	-0.6	-2.8, 1.6	0.6	-1.8, 3.0	0.0	-2.9, 2.9	-1.3	-4.4, 1.8	1.3	-2.0, 4.5	0.663
<i>P</i> for within- or between-group comparison**	0.482		0.567		0.607		0.982		0.404		0.441		
<b>Serum transferrin (g/l)‡§</b>	24, 23, 22		24, 23, 21		23, 20, 19								
<i>n</i>	24, 23, 22		24, 23, 21		23, 20, 19								
Baseline	2.3	2.2, 2.4	2.2	2.1, 2.3	2.2	2.1, 2.3							
Day 31	2.3	2.2, 2.4	2.3	2.2, 2.4	2.2	2.1, 2.3							
Day 45	2.2	2.1, 2.3	2.3	2.2, 2.4	2.2	2.1, 2.3							
Change from baseline to day 45¶	0.0	-0.1, 0.1	0.1	0.0, 0.2	0.0	-0.1, 0.0	-0.1	-0.2, 0.0	0.0	-0.1, 0.1	-0.1	-0.2, 0.0	0.018
<i>P</i> for within- or between-group comparison**	0.523		0.008		0.286		0.027		0.784		0.010		
<b>Transferrin saturation (%)‡§</b>	24, 23, 22		23, 23, 20		22, 20, 18								
<i>n</i>	24, 23, 22		23, 23, 20		22, 20, 18								
Baseline	16.1	13.8, 18.3	16.8	14.3, 19.2	16.1	13.4, 18.7							
Day 31	15.5	12.9, 18.1	16.9	14.6, 19.2	18.4	15.1, 21.6							
Day 45	15.4	12.4, 18.5	15.1	12.1, 18.1	17.8	14.8, 20.8							
Change from baseline to day 45¶	-0.6	-4.3, 3.0	-1.7	-5.6, 2.2	1.7	-2.7, 6.1	1.0	-4.3, 6.4	-2.4	-8.1, 3.4	3.4	-2.5, 9.2	0.517
<i>P</i> for within- or between-group comparison**	0.731		0.400		0.448		0.704		0.424		0.256		
<b>Serum hepcidin (µg/l)§††</b>	24, 22		24, 23		23, 19								
<i>n</i> §§	24, 22		24, 23		23, 19								
Baseline	49.3	42.0, 57.9	53.2	44.3, 63.8	67.9	57.7, 79.9							
Day 31	34.1	26.7, 43.5	34.6	26.7, 45.0	43.1	34.3, 54.2							
Change from baseline to day 31‡‡	0.69	0.51, 0.95	0.65	0.52, 0.82	0.64	0.52, 0.78	1.06	0.72, 1.57	1.09	0.75, 1.58	0.97	0.71, 1.34	0.908
<i>P</i> for within- or between-group comparison**	0.022		<0.001		<0.001		0.766		0.660		0.870		

Effect of type/amount of iron on absorption



Table 2. Continued

	Study group						Intervention effect†						
	High-Fe formula		Low-Fe formula		Fe drops		High-Fe formula v. low-Fe formula		High-Fe formula v. Fe drops		Fe drops v. low-Fe formula		<i>P</i> <sub>for intervention effect</sub>
	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI	
Plasma Zn (µmol/l)‡													
<i>n</i> /	24, 21, 22		24, 23, 21		22, 19, 20								
Baseline	12.8	11.6, 14.0	12.8	11.8, 13.8	12.8	12.0, 13.6							
Day 31	12.4	11.6, 13.2	13.0	12.0, 14.1	12.9	12.0, 13.8							
Day 45	11.7	10.9, 12.5	12.4	11.5, 13.3	12.6	11.7, 13.6							
Change from baseline to day 45¶	-1.1	-2.0, -0.2	-0.4	-1.5, 0.7	-0.2	-1.0, 0.7							
<i>P</i> for within- or between-group comparison**	0.020		0.480		0.723								0.342

\* All estimates are from linear random-intercept models with robust standard errors.

† The intervention effect is baseline to day 45 change (day 31 in the case of serum hepcidin) in one study group minus baseline to day 45 change (day 31 in the case of serum hepcidin) in another study group.

‡ Values are arithmetic means.

§ Model adjusted for sex and infection.

|| *n* at baseline, *n* at day 31, *n* at day 45.

¶ Expressed as a difference.

\*\* The within-group comparison is baseline to day 45 change within each study group. The between-group comparison is the intervention effect as described in footnote†.

†† Values are geometric means.

‡‡ Expressed as a ratio.

§§ *n* at baseline, *n* at day 31.

||| Model adjusted for time of day of blood sampling and infection.

## Discussion

This is the first study to investigate whether the mode of oral Fe administration or the amount of Fe habitually consumed will affect Fe absorption, Fe utilisation and Zn absorption in healthy, term, predominantly formula-fed, Fe-sufficient infants. We measured intestinal Fe absorption and systemic Fe utilisation directly by using both an oral and an intravenous tracer. This study showed that the type of Fe consumed, whether provided as an oral supplement or as a fortificant in infant formula daily for 45 d, did not affect Fe absorption, Fe utilisation or Zn absorption in infants. We also found no evidence that high intakes of fortification Fe compared with low intakes had an effect on these parameters.

Our results indicate that in well-nourished, predominantly formula-fed, Fe-sufficient infants Fe stores, rather than the mode of oral Fe administration or the habitual amount of Fe consumed, play a more important role in the regulation of Fe absorption. Fe stores, as determined by serum ferritin, were inversely correlated with Fe absorption and explained between 35 and 62 % of its total variability across the three study groups. This is supported by our previous research, which has shown that low Fe stores up-regulate Fe absorption from infant formula in healthy, formula-fed infants<sup>(55)</sup>, and other studies that have shown that Fe absorption from an Fe supplement is inversely related to infants' Fe stores<sup>(56)</sup>. In addition, we found evidence for a moderate-to-strong negative correlation between Fe absorption and serum hepcidin in all three groups in the current study. Hepcidin, a hormone produced primarily by the liver in response to high plasma Fe and inflammation<sup>(57,58)</sup>, regulates Fe absorption and its distribution to tissues<sup>(58)</sup>. Hepcidin binds to the Fe exporter ferroportin causing its degradation, and thus inhibiting efflux of Fe into plasma<sup>(58)</sup>. Hepcidin may also reduce Fe absorption by inhibiting the expression of enterocyte divalent metal ion transporter 1<sup>(59)</sup>. In contrast, Fe deficiency, hypoxia and erythropoietic activity down-regulate hepcidin production, which results in an increase in Fe absorption<sup>(60)</sup>. Except for formula and Fe drops intakes, no additional dietary data were available in the current study. However, as infants were not permitted to consume foods fortified with Fe or foods containing animal tissue, and as we provided all foods to be consumed during the study, it can be assumed that all or most of the Fe consumed during the trial was provided by the interventions. As these Fe intakes were within a very narrow range in each group, we did not investigate the correlations between dietary Fe intakes and Fe absorption, Fe stores or serum hepcidin. Nevertheless, we have previously shown that Fe intakes are not associated with either Fe absorption from infant formula or Fe stores in healthy, formula-fed infants<sup>(55)</sup>.

Fractional Fe absorption from infant formula in our study was comparable with previous reports<sup>(35,61-63)</sup>. Although daily consumption of approximately 500 ml of low-Fe formula (i.e. 1.2 mg Fe/d) for 1.5 months as the primary source of Fe resulted in reduced Fe stores and increased serum transferrin concentrations, all infants in the low-Fe formula group were Fe sufficient at the end of the study. However, if the low-Fe formula were to be consumed in the long term in the quantities

**Table 3.** Adjusted means at baseline, day 31 and day 45 with estimates of intervention effect for weight, length, head circumference and knee–heel length in the three study groups\* (Arithmetic means and 95 % confidence intervals)

	Study group						Intervention effect†						<i>P</i> <sub>for intervention effect</sub>
	High-Fe formula		Low-Fe formula		Fe drops		High-Fe formula v. low-Fe formula		High-Fe formula v. Fe drops		Fe drops v. low-Fe formula		
	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	
<b>Weight (kg)</b>													
<i>n</i> ‡	24, 22, 23		24, 23, 23		24, 20, 20								
Baseline	8.0	7.6, 8.4	8.3	7.9, 8.6	8.4	8.1, 8.7							
Day 31	8.5	8.1, 8.9	8.8	8.4, 9.1	8.9	8.6, 9.2							
Day 45	8.7	8.4, 9.1	9.0	8.6, 9.4	9.1	8.8, 9.4							
Change from baseline to day 45§	0.7	0.6, 0.8	0.8	0.6, 0.9	0.7	0.6, 0.8	0.0	-0.2, 0.1	0.0	-0.1, 0.1	0.0	-0.2, 0.1	0.917
<i>P</i> for within- or between-group comparison	<0.001		<0.001		<0.001		0.721		0.956		0.696		
<b>Length (cm)</b>													
<i>n</i>	24, 23		24, 23		24, 20								
Baseline	67.4	66.5, 68.3	68.0	67.2, 68.8	68.1	67.3, 68.9							
Day 45	70.0	69.1, 70.8	70.8	69.8, 71.7	70.9	70.0, 71.7							
Change from baseline to day 45§	2.5	2.2, 2.9	2.8	2.4, 3.2	2.8	2.4, 3.2	-0.3	-0.8, 0.3	-0.3	-0.9, 0.3	0.0	-0.6, 0.6	0.556
<i>P</i> for within- or between-group comparison	<0.001		<0.001		<0.001		0.345		0.369		0.991		
<b>Head circumference (cm)</b>													
<i>n</i>	24, 23		24, 22		24, 20								
Baseline	43.8	43.4, 44.3	44.1	43.6, 44.5	44.3	43.9, 44.8							
Day 45	44.9	44.4, 45.3	45.3	44.8, 45.8	45.5	45.1, 46.0							
Change from baseline to day 45§	1.0	0.9, 1.1	1.2	1.1, 1.3	1.2	1.1, 1.3	-0.2	-0.4, 0.0	-0.2	-0.4, 0.0	0.0	-0.2, 0.1	0.052
<i>P</i> for within- or between-group comparison	<0.001		<0.001		<0.001		0.022		0.046		0.709		
<b>Knee–heel length (mm)</b>													
<i>n</i>	23, 23		24, 23		24, 20								
Baseline	66.0	62.6, 69.4	66.6	63.8, 69.3	66.4	63.6, 69.2							
Day 45	75.0	72.3, 77.7	76.5	73.5, 79.6	75.8	72.6, 78.9							
Change from baseline to day 45§	9.0	7.4, 10.6	10.0	8.3, 11.7	9.4	7.7, 11.0	-1.0	-3.3, 1.4	-0.4	-2.7, 1.9	-0.6	-2.9, 1.8	0.724
<i>P</i> for within- or between-group comparison	<0.001		<0.001		<0.001		0.424		0.751		0.632		

\* All estimates are from linear random-intercept models with robust standard errors adjusted for sex.

† The intervention effect is baseline to day 45 change in one study group minus baseline to day 45 change in another study group.

‡ *n* at baseline, *n* at day 31, *n* at day 45.

§ Expressed as a difference.

|| The within-group comparison is baseline to day 45 change within each study group. The between-group comparison is the intervention effect as described in footnote†.

¶ *n* at baseline, *n* at day 45.

**Table 4.** Absorption of iron (from an 8.1 or 8.3 mg dose) and zinc (from a 2.4 or 2.5 mg dose) in healthy, 7-month-old, Swedish infants habitually consuming high-iron formula, low-iron formula or iron drops\* (Geometric/arithmetic means and 95 % confidence intervals)

	Study group									<i>P</i> <sub>for group comparison</sub>
	High-Fe formula			Low-Fe formula			Fe drops			
	<i>n</i>	Mean	95 % CI	<i>n</i>	Mean	95 % CI	<i>n</i>	Mean	95 % CI	
Fractional Fe absorption (%)†	22	6.8	5.8, 7.9	22	7.4	5.8, 9.5	19	7.7	6.5, 9.2	0.534
Erythrocyte Fe utilisation (%)†	22	88.8	83.7, 94.2	22	86.3	78.6, 94.8	19	88.6	84.7, 92.6	0.865
Fractional Zn absorption (%)‡	22	32.1	29.7, 34.5	19	29.9	27.1, 32.7	19	32.7	30.4, 35.0	0.284

\* All estimates are from linear regression models with robust standard errors.

† Values are geometric means.

‡ Values are arithmetic means.


**Table 5.** Univariate correlations between iron absorption and iron status indices in healthy, 7-month-old, Swedish infants habitually consuming high-iron formula, low-iron formula or iron drops\* ( $\beta$ -Coefficients and 95 % confidence intervals)

	Log Fe absorption (%)														
	High-Fe formula					Low-Fe formula					Fe drops				
	<i>n</i>	$\beta$	95 % CI	<i>R</i> <sup>2</sup>	<i>P</i> <sub>for <math>\beta</math></sub>	<i>n</i>	$\beta$	95 % CI	<i>R</i> <sup>2</sup>	<i>P</i> <sub>for <math>\beta</math></sub>	<i>n</i>	$\beta$	95 % CI	<i>R</i> <sup>2</sup>	<i>P</i> <sub>for <math>\beta</math></sub>
Hb (g/l)†	21	-0.001	-0.025, 0.023	0.001	0.924	21	0.021	-0.014, 0.056	0.079	0.216	16	-0.002	-0.040, 0.037	0.001	0.919
Mean corpuscular volume (fl)†	21	-0.022	-0.063, 0.019	0.063	0.273	21	-0.036	-0.175, 0.103	0.015	0.596	16	-0.035	-0.105, 0.034	0.079	0.292
Log serum ferritin ( $\mu$ g/l)‡	22	-0.415	-0.680, -0.149	0.347	0.004	22	-0.609	-0.918, -0.300	0.458	0.001	19	-0.512	-0.718, -0.307	0.620	<0.001
Serum Fe ( $\mu$ mol/l)†	21	0.015	-0.033, 0.063	0.022	0.526	21	0.080	0.025, 0.136	0.327	0.007	16	0.011	-0.046, 0.068	0.012	0.683
Serum transferrin (g/l)†	21	0.076	-0.575, 0.727	0.003	0.809	21	0.820	0.042, 1.597	0.204	0.040	16	0.605	-0.090, 1.300	0.199	0.083
Transferrin saturation (%)†	21	0.006	-0.018, 0.030	0.013	0.630	21	0.044	0.003, 0.086	0.208	0.038	16	-0.002	-0.032, 0.028	0.001	0.904
Log serum hepcidin ( $\mu$ g/l)†	21	-0.280	-0.548, -0.011	0.200	0.042	21	-0.710	-1.051, -0.368	0.500	<0.001	16	-0.540	-0.829, -0.250	0.533	0.001


\* All estimates are from linear regression models. Fe indices were measured on day 31.

† Infants with a C-reactive protein concentration >5 mg/l or a missing value on day 31 were excluded: *n* 1 (missing value for C-reactive protein) in the high-Fe formula group, *n* 1 (C-reactive protein >5 mg/l) in the low-Fe formula group and *n* 3 (*n* 1, missing value for C-reactive protein; *n* 2, C-reactive protein >5 mg/l) in the Fe drops group for Hb, mean corpuscular volume, serum Fe, serum transferrin and transferrin saturation; *n* 0 in the high-Fe formula group, *n* 1 (C-reactive protein >5 mg/l) in the low-Fe formula group and *n* 2 (C-reactive protein >5 mg/l) in the Fe drops group for serum hepcidin.

‡ Values were corrected for infection<sup>(53)</sup>.



**Fig. 2.** Scatter plot depicting the relationship between fractional iron absorption and serum ferritin concentration (measured on day 31) in healthy, 7-month-old, Swedish infants habitually consuming high-iron formula (■, *n* 22), low-iron formula (●, *n* 22) or iron drops (▲, *n* 19). Serum ferritin concentrations were corrected for infection for all infants with a C-reactive protein concentration >5 mg/l<sup>(63)</sup>. Linear regression on log-transformed values showed a negative correlation between fractional iron absorption and serum ferritin concentration across the three groups ( $r = -0.64$ ,  $P < 0.001$ ,  $n$  63).



**Fig. 3.** Scatter plot depicting the relationship between fractional iron absorption and serum hepcidin concentration (measured on day 31) in healthy, 7-month-old, Swedish infants habitually consuming high-iron formula (■, *n* 21), low-iron formula (●, *n* 21) or iron drops (▲, *n* 16). Infants with an elevated C-reactive protein concentration (>5 mg/l) were excluded. Linear regression on log-transformed values showed a negative correlation between fractional iron absorption and serum hepcidin concentration across the three groups ( $r = -0.59$ ,  $P < 0.001$ ,  $n$  58).

observed in our study and in the absence of Fe-rich foods, it is unlikely that it would provide sufficient Fe to maintain adequate Fe status in infancy – a conclusion in line with recent recommendations on fortification levels of infant and follow-on formulae<sup>(64)</sup>.

Few studies have determined Fe availability to infants from supplements. The 7.7% Fe absorption from Fe drops in our study is similar to that of 7.6% found by Heinrich *et al.*<sup>(65)</sup> who administered 10 mg of ferrous sulphate to 1–18-month-old Fe-sufficient infants and similar to that of 6.6–8.5% from 3 mg of ferrous sulphate previously found by our group in 6–9-month-old Fe-sufficient infants<sup>(66)</sup>. In contrast, at 13.7%, Fe absorption from 5 mg of ferrous sulphate appeared to be higher in

13-month-old children in the study by Abrams *et al.*<sup>(56)</sup> compared with ours; however, the infants had poorer Fe status compared with the infants in our study. Furthermore, the supplement in the study by Abrams *et al.*<sup>(56)</sup> was administered with apple juice that contained ascorbic acid at a 3:1 molar ratio of ascorbic acid:Fe, which could also help explain the higher Fe absorption in their study compared with ours. The addition of ascorbic acid at a molar ratio of  $\geq 2:1$  of ascorbic acid:Fe has been shown to enhance the absorption of Fe from ferrous sulphate<sup>(67)</sup>. In our study, the Fe drops were administered 2 h after the ingestion of 150 ml of the formula with no added Fe (131.3 mg ascorbic acid/l) and  $\geq 1$  h before the next meal was consumed. As the formula would have emptied from the stomach after 2 h<sup>(68)</sup> and the drops would have been absorbed before the next meal was provided, it is unlikely that the ascorbic acid in the formula would have interacted with the Fe drops. Fomon *et al.*<sup>(69)</sup> found that only 4.4% of Fe was incorporated into erythrocytes in 2-month-old formula-fed infants from 8 mg ferrous sulphate administered with ascorbic acid at a 1:1 molar ratio of ascorbic acid:Fe.

It is still uncertain whether the current study lends support to our previous report that fortification Fe is primarily utilised for Hb synthesis<sup>(14)</sup>. The consumption of 6.4 mg of fortification Fe per day resulted in a 6.3 g/l higher Hb concentration compared with that achieved with Fe drops and does appear to confirm the earlier observation. Although the high-Fe formula group consumed 0.6 mg/d more Fe from the intervention compared with the Fe drops group, this is not enough to explain the differences observed in Hb concentrations. At 7% Fe absorption, 0.6 mg more Fe consumed per day converts to approximately 1.9 mg (0.04 mg/d for 45 d) more Fe absorbed by the high-Fe formula group over the 45-d intervention compared with the Fe drops group. This is much less than the amount of additional Fe needed to raise Hb concentration by 6.3 g/l in an 8.5-kg infant with a blood volume of approximately 550 ml, which would be approximately 12 mg. Nevertheless, there was no evidence that the incorporation of infused Fe into Hb was greater in the high-Fe formula group than in the Fe drops group. The labelled Fe infusion was given 30 min after the isotopic meal, so that the Fe incorporation of the two isotopes would be expected to be similar. In contrast to our previous results<sup>(14)</sup>, we found no evidence that Fe supplements result in higher Fe stores compared with fortification Fe, which is also unlikely to be explained by the lower amount of total Fe absorbed from the interventions. The Fe drops group absorbed only 1.9 mg less Fe over 45 d than the high-Fe formula group, and in adults 8–10 mg of additional storage Fe is needed to increase serum ferritin by 1 µg/l<sup>(70)</sup>.

Fe supplements have been shown to impair Zn absorption in adults when both minerals are provided together as a supplement in aqueous solutions at a high Fe:Zn molar ratio<sup>(71)</sup>. Moreover, Fe supplements given together with Zn supplements appear to result in reduced plasma Zn concentrations in infants<sup>(28)</sup>. In contrast, we found no effect of Fe supplements given alone on Zn absorption or status in infants. This confirms our previous findings of no effect of Fe supplements on Zn absorption in infants<sup>(29)</sup>, and is in line with previous research showing that Fe supplements provided to infants alone in the



range of 7.5–30 mg Fe/d do not have adverse effects on Zn status<sup>(27,28)</sup>. The results of our study support the limited research that shows no evidence that consumption of foods fortified with Fe has a negative effect on Zn absorption<sup>(30,32)</sup> or Zn status<sup>(32,33)</sup> in young children. The absorption of Zn from the study formulae was similar to that previously reported in infants<sup>(36)</sup>. Dietary non-haem Fe is transported into enterocytes by the transmembrane protein divalent metal ion transporter 1<sup>(72)</sup>, whereas Zn uptake and transport across enterocytes is regulated by specialised Zn transporters<sup>(73)</sup>. However, some Zn transporters (e.g. Zn-regulated transporter/Fe-regulated transporter-like proteins 8 and 14; ZIP8 and ZIP14) have recently been found to be capable of transporting Fe into mammalian cells<sup>(74,75)</sup>. Therefore, it can be speculated that when an excessive amount of Fe is consumed together with Zn in a water solution Fe may inhibit ZIP-mediated Zn transport, resulting in decreased Zn absorption and reduced Zn concentrations. This inhibition would not occur when Fe supplements are ingested alone. In contrast, when Fe is provided in a meal as fortification Fe, it interacts with dietary components that can reduce the number of Fe cations available for absorption compared with supplemental Fe provided in an aqueous solution, and therefore it does not exert the same negative effect on Zn absorption or status. Thus, it may be prudent to suggest that in situations when Fe supplements are required they are provided to infants alone or are provided as fortification Fe along with fortification Zn in infant formula.

Unlike recent reviews showing that Fe supplementation or fortification may result in reduced weight gain and length in Fe-deficient and Fe-sufficient infants<sup>(28,76)</sup>, we found no evidence that the type or dose of Fe consumed had a negative effect on physical growth in healthy, Fe-sufficient infants. However, the considerably shorter duration of our study compared with others might have prevented us from observing an effect.

It must be noted that we did not provide placebo drops to the formula groups, which could have potentially biased the results. However, we have shown previously that there is no difference in compliance to placebo or Fe drops in Swedish infants<sup>(77)</sup>. Furthermore, despite the Fe drops group not being blinded, we found no difference among the three groups in the amount of the assigned formula consumed during the trial. Finally, adherence to the allocated intervention was excellent in all groups in the current study.

In summary, Fe can be safely provided to healthy, term, Fe-sufficient infants as either a supplement or a fortificant, within the amounts and duration of intake investigated in our study, as we found no evidence that the mode of oral Fe administration or the amount of Fe habitually consumed altered infant Fe absorption, systemic Fe utilisation, Zn absorption, plasma Zn or physical growth. As observed previously, consumption of fortification Fe compared with supplemental Fe resulted in a greater Hb concentration. However, unlike previously shown, consumption of Fe drops did not result in increased Fe stores compared with fortification Fe. Daily intakes of approximately 500 ml of low-Fe formula (2.3 mg Fe/l) in the absence of other sources of Fe are insufficient to maintain Fe stores in >6-month-old infants. Our results also demonstrate that Fe stores and hepcidin regulate Fe absorption from both Fe

supplements and infant formula in Fe-sufficient, predominantly formula-fed infants.

## Acknowledgements

The authors thank Åsa Sundström and Camilla Steinvall Lindberg for participant recruitment and data collection, Monika Brändström for translating all protocols from English to Swedish and Jasmin Tajeri Foman for sample analysis.

This study was supported by the New Zealand Foundation for Research, Science and Technology (grant number UMEA0901 to E. A. S.-G.); ETH Zurich, Switzerland; the Umeå University Foundation; and the Västerbotten County Council (ALF). E. A. S.-G. was supported by a New Zealand Science and Technology Postdoctoral Fellowship from the Foundation for Research, Science and Technology (fellowship grant no. UMEA0901). Semper AB, Sweden, generously provided the study formulae and the fruit- and vegetable-based infant foods. The funders had no role in designing or conducting the study, in the collection, management, analysis or interpretation of the data and had no input into the preparation, review or approval of the manuscript.

The authors' responsibilities were as follows: E. A. S.-G., M. D., O. H., R. F. H., T. L., B. L., C. Z. and I. M. E. designed the study; E. A. S.-G., M. D., O. H. and T. L. conducted the study; C. Z. measured plasma Zn concentrations and the Fe and Zn isotopic composition; E. A. S.-G. performed statistical analyses, wrote the paper and took primary responsibility for the final content; and all the authors provided a critical review of the manuscript and read and approved the final version of the manuscript.

O. H. and B. L. are members of the Scientific Advisory Board of Semper and Hero. M. D., O. H., T. L. and B. L. have received research support from Semper and Hero unrelated to the present study. The remaining authors declare no conflicts of interest related to the study.

## References

- McLean E, Cogswell M, Egli I, *et al.* (2009) Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993–2005. *Public Health Nutr* **12**, 444–454.
- Lozoff B, Beard J, Connor J, *et al.* (2006) Long-lasting neural and behavioral effects of iron deficiency in infancy. *Nutr Rev* **64**, S34–S43.
- Lind T, Lönnerdal B, Stenlund H, *et al.* (2003) A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc. *Am J Clin Nutr* **77**, 883–890.
- Berger J, Ninh NX, Khan NC, *et al.* (2006) Efficacy of combined iron and zinc supplementation on micronutrient status and growth in Vietnamese infants. *Eur J Clin Nutr* **60**, 443–454.
- Iannotti LL, Tielsch JM, Black MM, *et al.* (2006) Iron supplementation in early childhood: health benefits and risks. *Am J Clin Nutr* **84**, 1261–1276.
- Ziegler EE, Nelson SE & Jeter JM (2009) Iron status of breastfed infants is improved equally by medicinal iron and iron-fortified cereal. *Am J Clin Nutr* **90**, 76–87.

7. Szymlek-Gay EA, Ferguson EL, Heath ALM, *et al.* (2009) Food-based strategies improve iron status in toddlers: a randomized controlled trial. *Am J Clin Nutr* **90**, 1541–1551.
8. Morley R, Abbott R, Fairweather-Tait S, *et al.* (1999) Iron fortified follow on formula from 9 to 18 months improves iron status but not development or growth: a randomised trial. *Arch Dis Child* **81**, 247–252.
9. Daly A, MacDonald A, Aukett A, *et al.* (1996) Prevention of anaemia in inner city toddlers by an iron supplemented cows' milk formula. *Arch Dis Child* **75**, 9–16.
10. Gill DG, Vincent S & Segal DS (1997) Follow-on formula in the prevention of iron deficiency: a multicentre study. *Acta Paediatr* **86**, 683–689.
11. Moffatt ME, Longstaffe S, Besant J, *et al.* (1994) Prevention of iron deficiency and psychomotor decline in high-risk infants through use of iron-fortified infant formula: a randomized clinical trial. *J Pediatr* **125**, 527–534.
12. Lind T, Seswandhana R, Persson LÅ, *et al.* (2008) Iron supplementation of iron-replete Indonesian infants is associated with reduced weight-for-age. *Acta Paediatr* **97**, 770–775.
13. Dewey KG, Domellöf M, Cohen RJ, *et al.* (2002) Iron supplementation affects growth and morbidity of breast-fed infants: results of a randomized trial in Sweden and Honduras. *J Nutr* **132**, 3249–3255.
14. Domellöf M, Lind T, Lönnerdal B, *et al.* (2008) Effects of mode of oral iron administration on serum ferritin and haemoglobin in infants. *Acta Paediatr* **97**, 1055–1060.
15. Andersson M & Hurrell RF (2010) Prevention of iron deficiency in infancy, childhood and adolescence. *Ann Nestlé Engl* **68**, 120–131.
16. Brittenham GM, Andersson M, Egli I, *et al.* (2014) Circulating non-transferrin-bound iron after oral administration of supplemental and fortification doses of iron to healthy women: a randomized study. *Am J Clin Nutr* **100**, 813–820.
17. Britton RS, Leicester KL & Bacon BR (2002) Iron toxicity and chelation therapy. *Int J Hematol* **76**, 219–228.
18. Kaur D, Peng J, Chinta SJ, *et al.* (2007) Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. *Neurobiol Aging* **28**, 907–913.
19. Lozoff B, Castillo M, Clark KM, *et al.* (2012) Iron-fortified vs low-iron infant formula: developmental outcome at 10 years. *Arch Pediatr Adolesc Med* **166**, 208–215.
20. Soofi S, Cousens S, Iqbal SP, *et al.* (2013) Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial. *Lancet* **382**, 29–40.
21. Lönnerdal B (2000) Dietary factors influencing zinc absorption. *J Nutr* **130**, 1378S–1383S.
22. Brown KH (1998) Effect of infections on plasma zinc concentration and implications for zinc status assessment in low-income countries. *Am J Clin Nutr* **68**, 425S–429S.
23. Krebs NF, Miller LV & Hambidge KM (2014) Zinc deficiency in infants and children: a review of its complex and synergistic interactions. *Paediatr Int Child Health* **34**, 279–288.
24. Brown KH, Pearson JM, Baker SK, *et al.* (2009) Preventive zinc supplementation among infants, preschoolers, and older prepubertal children. *Food Nutr Bull* **30**, S12–S40.
25. Georgieff MK (2007) Nutrition and the developing brain: nutrient priorities and measurement. *Am J Clin Nutr* **85**, 614S–620S.
26. Lim KH, Riddell LJ, Nowson CA, *et al.* (2013) Iron and zinc nutrition in the economically-developed world: a review. *Nutrients* **5**, 3184–3211.
27. Fischer Walker C, Kordas K, Stoltzfus RJ, *et al.* (2005) Interactive effects of iron and zinc on biochemical and functional outcomes in supplementation trials. *Am J Clin Nutr* **82**, 5–12.
28. Pasricha SR, Hayes E, Kalumba K, *et al.* (2013) Effect of daily iron supplementation on health in children aged 4–23 months: a systematic review and meta-analysis of randomised controlled trials. *Lancet Glob Health* **1**, e77–e86.
29. Domellöf M, Hernell O, Abrams SA, *et al.* (2009) Iron supplementation does not affect copper and zinc absorption in breastfed infants. *Am J Clin Nutr* **89**, 185–190.
30. Fairweather-Tait SJ, Wharf SG & Fox TE (1995) Zinc absorption in infants fed iron-fortified weaning food. *Am J Clin Nutr* **62**, 785–789.
31. Davidsson L, Almgren A, Sandström B, *et al.* (1995) Zinc absorption in adult humans: the effect of iron fortification. *Br J Nutr* **74**, 417–425.
32. Esamai F, Liechty E, Ikemeri J, *et al.* (2014) Zinc absorption from micronutrient powder is low but is not affected by iron in Kenyan infants. *Nutrients* **6**, 5636–5651.
33. Morgan EJ, Heath A-LM, Szymlek-Gay EA, *et al.* (2010) Red meat and a fortified manufactured toddler milk drink increase dietary zinc intakes without affecting zinc status of New Zealand toddlers. *J Nutr* **140**, 2221–2226.
34. Gera T, Sachdev HS & Boy E (2012) Effect of iron-fortified foods on hematologic and biological outcomes: systematic review of randomized controlled trials. *Am J Clin Nutr* **96**, 309–324.
35. Davidsson L, Ziegler EE, Kastenmayer P, *et al.* (2000) Erythrocyte incorporation of iron by infants: iron bioavailability from a low-iron infant formula and an evaluation of the usefulness of correcting erythrocyte incorporation values, using a reference dose or plasma ferritin concentrations. *Br J Nutr* **84**, 847–853.
36. Abrams SA, Griffin IJ & Davila PM (2002) Calcium and zinc absorption from lactose-containing and lactose-free infant formulas. *Am J Clin Nutr* **76**, 442–446.
37. Lohman TG, Roche AF & Martorell R (1988) *Anthropometric Standardization Reference Manual*. Champaign, IL: Human Kinetics Publications.
38. World Health Organization (2010) *WHO Anthro for Personal Computers, Version 3.2.2: Software for Assessing Growth and Development of the World's Children*. Geneva: WHO. <http://www.who.int/childgrowth/software/en/> (accessed December 2014).
39. Dainty JR, Roe MA, Teucher B, *et al.* (2003) Quantification of unlabelled non-haem iron absorption in human subjects: a pilot study. *Br J Nutr* **90**, 503–506.
40. Roe MA, Heath AL, Oyston SL, *et al.* (2005) Iron absorption in male C282Y heterozygotes. *Am J Clin Nutr* **81**, 814–821.
41. World Health Organization Multicentre Growth Reference Study Group (2006) *WHO Child Growth Standards. Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development*. Geneva: WHO.
42. Abrams SA (2008) Assessing mineral metabolism in children using stable isotopes. *Pediatr Blood Cancer* **50**, 438–441.
43. Rustad P, Felding P, Lahti A, *et al.* (2004) Descriptive analytical data and consequences for calculation of common reference intervals in the Nordic Reference Interval Project 2000. *Scand J Clin Lab Invest* **64**, 343–370.
44. Walczyk T, Davidsson L, Zavaleta N, *et al.* (1997) Stable isotope labels as a tool to determine the iron absorption by Peruvian school children from a breakfast meal. *Fresenius J Anal Chem* **359**, 445–449.
45. Bratteby LE (1968) Studies on erythro-kinetics in infancy. XI. The change in circulating red cell volume during the first five months of life. *Acta Paediatr Scand* **57**, 215–224.
46. Wegmüller R, Tay F, Zeder C, *et al.* (2014) Zinc absorption by young adults from supplemental zinc citrate is comparable



- with that from zinc gluconate and higher than from zinc oxide. *J Nutr* **144**, 132–136.
47. Friel JK, Naake VL Jr, Miller LV, *et al.* (1992) The analysis of stable isotopes in urine to determine the fractional absorption of zinc. *Am J Clin Nutr* **55**, 473–477.
  48. Gibson RS (2005) *Principles of Nutritional Assessment*, 2nd ed. New York: Oxford University Press.
  49. World Health Organization (2001) *Iron Deficiency Anaemia: Assessment, Prevention and Control. A Guide for Programme Managers. WHO/NHD/01.3*. Geneva: WHO.
  50. Domellöf M, Dewey KG, Lönnerdal B, *et al.* (2002) The diagnostic criteria for iron deficiency in infants should be reevaluated. *J Nutr* **132**, 3680–3686.
  51. Saarinen UM & Siimes MA (1977) Developmental changes in serum iron, total iron-binding capacity, and transferrin saturation in infancy. *J Pediatr* **91**, 875–877.
  52. Brown KH, Rivera JA, Bhutta Z, *et al.* (2004) International Zinc Nutrition Consultative Group (IZiNCG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control. *Food Nutr Bull* **25**, S99–S203.
  53. Thurnham DI, McCabe LD, Haldar S, *et al.* (2010) Adjusting plasma ferritin concentrations to remove the effects of sub-clinical inflammation in the assessment of iron deficiency: a meta-analysis. *Am J Clin Nutr* **92**, 546–555.
  54. Mburu AS, Thurnham DI, Mwaniki DL, *et al.* (2008) The influence and benefits of controlling for inflammation on plasma ferritin and hemoglobin responses following a multi-micronutrient supplement in apparently healthy, HIV+ Kenyan adults. *J Nutr* **138**, 613–619.
  55. Szymlek-Gay EA, Lönnerdal B, Abrams SA, *et al.* (2012) alpha-Lactalbumin and casein-glycomacropeptide do not affect iron absorption from formula in healthy term infants. *J Nutr* **142**, 1226–1231.
  56. Abrams SA, O'Brien KO, Wen J, *et al.* (1996) Absorption by 1-year-old children of an iron supplement given with cow's milk or juice. *Pediatr Res* **39**, 171–175.
  57. Nemeth E, Tuttle MS, Powelson J, *et al.* (2004) Hcpidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science* **306**, 2090–2093.
  58. Ganz T (2011) Hcpidin and iron regulation, 10 years later. *Blood* **117**, 4425–4433.
  59. Brasse-Lagnel C, Karim Z, Letteron P, *et al.* (2011) Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. *Gastroenterology* **140**, 1261–1271.
  60. Nemeth E & Ganz T (2009) The role of hepcidin in iron metabolism. *Acta Haematol* **122**, 78–86.
  61. Kastenmayer P, Davidsson L, Galan P, *et al.* (1994) A double stable isotope technique for measuring iron absorption in infants. *Br J Nutr* **71**, 411–424.
  62. Fomon SJ, Ziegler EE & Nelson SE (1993) Erythrocyte incorporation of ingested <sup>58</sup>Fe by 56-day-old breast-fed and formula-fed infants. *Pediatr Res* **33**, 573–576.
  63. Stekel A, Olivares M, Pizarro F, *et al.* (1986) Absorption of fortification iron from milk formulas in infants. *Am J Clin Nutr* **43**, 917–922.
  64. Hernell O, Fewtrell MS, Georgieff MK, *et al.* (2015) Summary of current recommendations on iron provision and monitoring of iron status for breastfed and formula-fed infants in resource-rich and resource-constrained countries. *J Pediatr* **167**, S40–S47.
  65. Heinrich HC, Gabbe EE, Whang DH, *et al.* (1975) Ferrous and hemoglobin-<sup>59</sup>Fe absorption from supplemented cow milk in infants with normal and depleted iron stores. *Z Kinderbeilkd* **120**, 251–258.
  66. Domellöf M, Lönnerdal B, Abrams SA, *et al.* (2002) Iron absorption in breast-fed infants: effects of age, iron status, iron supplements, and complementary foods. *Am J Clin Nutr* **76**, 198–204.
  67. Hurrell R (2002) How to ensure adequate iron absorption from iron-fortified food. *Nutr Rev* **60**, S7–S15.
  68. Cavell B (1981) Gastric emptying in infants fed human milk or infant formula. *Acta Paediatr Scand* **70**, 639–641.
  69. Fomon SJ, Ziegler EE, Nelson SE, *et al.* (1995) Erythrocyte incorporation of iron by 56-day-old infants fed a <sup>58</sup>Fe-labeled supplement. *Pediatr Res* **38**, 373–378.
  70. Zimmermann MB (2008) Methods to assess iron and iodine status. *Br J Nutr* **99**, S2–S9.
  71. Sandström B, Davidsson L, Cederblad A, *et al.* (1985) Oral iron, dietary ligands and zinc absorption. *J Nutr* **115**, 411–414.
  72. Garrick MD & Garrick LM (2009) Cellular iron transport. *Biochim Biophys Acta* **1790**, 309–325.
  73. Cousins RJ (2010) Gastrointestinal factors influencing zinc absorption and homeostasis. *Int J Vitam Nutr Res* **80**, 243–248.
  74. Jenkitkasemwong S, Wang CY, Mackenzie B, *et al.* (2012) Physiologic implications of metal-ion transport by ZIP14 and ZIP8. *Biometals* **25**, 643–655.
  75. Wang C-Y, Jenkitkasemwong S, Duarte S, *et al.* (2012) ZIP8 is an iron and zinc transporter whose cell-surface expression is up-regulated by cellular iron loading. *J Biol Chem* **287**, 34032–34043.
  76. Sachdev H, Gera T & Nestel P (2006) Effect of iron supplementation on physical growth in children: systematic review of randomised controlled trials. *Public Health Nutr* **9**, 904–920.
  77. Berglund S, Westrup B & Domellöf M (2010) Iron supplements reduce the risk of iron deficiency anemia in marginally low birth weight infants. *Pediatrics* **126**, e874–e883.